Skip to main content
https://www.youtube.com/watch?v=jEc03mATQyQ

Shaping the future of clinical research with Purpose

Your partner in clinical trials, epidemiology, and innovation

Purpose Life Sciences is an Impact Research Organization that helps sponsors and partners redefine clinical trials with speed, adaptability, and global partnerships to evaluate life-saving therapeutics.

450+

adaptive / conventional / platform clinical trials run

2,000+

publications across TAs and advanced trial design

200,000+

citations of our experts by scholarly publications

Innovative approaches are needed to address long-standing challenges

The way our industry conducts clinical trials hasn’t changed in decades. At Purpose Life Sciences, we have pioneered a new model for clinical development that takes a methodical approach to incorporating epidemiological data and translating that into trial planning, trial conduct, and trial results strategy. This methodology ensures you always have the most highly efficient clinical trial management possible.

See Our Approach

There’s a better way to do clinical trials. We’ve re-examined the entire clinical trial process and applied expertise, science, and technologies to significantly shorten time, cost, and effort spent on operationalizing them. Elevate trial excellence. Make timely decisions. Move forward faster.

Augmented Epidemiology

We have access to evidence gap data with the ability to clean and harmonize data that informs critical trial protocols.

Global Public Health

We establish global clinical trial infrastructure in emerging geographies to improve quality of care and patient outcomes.

Our Approach

We design and deliver clinical trials with speed, adaptability, and global partnerships to evaluate lifesaving therapeutics.
OUR PUBLICATIONS

Explore Our Published Works

View All

Filter

Global HIV control: is the glass half empty or half full?

Global HIV control: is the glass half empty or half full?

The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient.
August 2, 20234 min
PEPFAR at 20 – A Game-Changing Impact on HIV in Africa

PEPFAR at 20 – A Game-Changing Impact on HIV in Africa

Interview with Jean Nachega on PEPFAR’s achievements and remaining challenges in HIV prevention and treatment in sub-Saharan Africa.
July 7, 20231 min
Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial

Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19.
May 23, 20232 min

“We stand at the forefront of innovation ready to partner with our research constituents to tackle some of the world’s biggest public health challenges.”

Ed Mills, PhD, FRCP (Lond, Edin)Chief Executive Officer